Scorpion Therapeutics to Present STX-478 Initial Phase 1/2 Data at ESMO Congress 2024
2024年8月20日 - 2:02AM
ビジネスワイヤ(英語)
Scorpion Therapeutics, Inc. (“Scorpion”), a pioneering
clinical-stage oncology company dedicated to transforming the lives
of cancer patients by redefining the frontier of precision
oncology, today announced that it was selected to present initial,
first-in-human clinical results from the Phase 1/2 study of
STX-478, a mutant-selective PI3Kα inhibitor, in advanced solid
tumor patients in a Proffered Paper late-breaking session at the
European Society for Medical Oncology (“ESMO”) Congress 2024,
taking place September 13 – 17, 2024 in Barcelona, Spain.
“The presentation of first-in-human clinical data for our lead
candidate, STX-478, marks an important milestone for patients
living with advanced solid tumors driven by PI3Kα mutations,
especially HR+/HER2- breast cancer, and for Scorpion as we work to
broaden the reach and impact of precision oncology for patients
with high unmet medical need,” said Mark Chao, M.D., Ph.D., Chief
Medical Officer of Scorpion. “While PI3Kα has been one of the
highest profile targets in cancer for years, current treatment
options suffer from toxicity limitations and subpar efficacy due to
a lack of mutant selectivity. These initial data will provide early
insight into how STX-478's differentiated profile translates to
potentially superior outcomes in PI3Kα-mutated cancers, and we look
forward to presenting initial assessments of safety,
pharmacokinetic and pharmacodynamic data and preliminary efficacy
data at the ESMO 2024 Congress."
Details of the Proffered Paper presentation are as follows:
Title: First-in-human Results of STX-478, a
Mutant-selective PI3Kα Inhibitor, in Advanced Solid Tumor Patients
Presentation Number: LBA27 Session Name: Proffered
paper session 2: Developmental therapeutics (ID 156) Session
Date & Time: Sunday, September 15, 2024, at 14:45 CEST –
16:15 CEST (8:45 a.m. – 10:15 a.m. ET) Presentation Time:
14:55 CEST – 15:05 CEST (8:55 a.m. – 9:05 a.m. ET) Location:
Salamanca Auditorium - Hall 5 Presenter: Alberto J. Montero,
M.D. (University Hospitals Cleveland, OH, USA)
According to ESMO, the late-breaking abstract will be published
via the ESMO website at 00:05 CEST on September 15 (6:05 p.m. ET on
September 14). Data presented at the conference will be available
to view in the "Publications & Presentations" section of the
Scorpion website (https://www.scorpiontx.com/publications-posters/)
following the ESMO 2024 Congress.
About STX-478
STX-478 was designed to improve outcomes in patients harboring
PI3Kα mutations, one of the most prevalent drivers of cancer,
occurring in over 166,000 patients per year with breast,
gynecological and other solid tumors in the United States alone. In
preclinical models, STX-478 demonstrated robust activity across a
range of PI3Kα mutations while sparing wild-type PI3Kα inhibition
in normal tissues; previous generations of non-selective PI3Kα
inhibitors have limited patient benefit due to these on-target
toxicities. Scorpion’s Phase 1/2 clinical trial is a multi-center,
global, open-label study designed to evaluate the safety and
tolerability of STX-478 in multiple ascending doses for patients
with locally advanced or metastatic HR+/HER2- breast cancer and
other solid tumors driven by PI3Kα mutations. The program entered
the clinic in 2023 and has rapidly advanced, now in multiple
expansion cohorts across a range of solid tumors and in breast
cancer as monotherapy and in combinations with fulvestrant and
CDK4/6 inhibitors. To learn more about the first-in-human trial of
STX-478, please visit this page.
About Scorpion Therapeutics
Scorpion is a pioneering clinical-stage oncology company
redefining the frontier of precision medicine to deliver optimized
and transformational therapies for larger populations of patients
with cancer. Scorpion has built a proprietary and fully-integrated
platform of the most advanced technologies across cancer biology,
medicinal chemistry, and data sciences, with the goal of
consistently and rapidly creating exquisitely selective small
molecule compounds against an unprecedented spectrum of targets.
Scorpion aims to leverage its platform to advance a broad pipeline
of wholly-owned, optimized compounds across three target
categories: best-in-class molecules targeting validated oncogene
targets; first-in-class molecules for previously undruggable
targets; and first-in-class molecules for novel cancer targets. For
more information, visit www.scorpiontx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240819324186/en/
Media Contact: Ethan Metelenis Precision AQ
ethan.metelenis@precisionaq.com
Investor Contact: Emiley Demick Precision AQ
emiley.demick@precisionaq.com